BCAX — Bicara Therapeutics Inc. Common Stock

Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts. Bicara Therapeutics Inc. is a subsidiary of Biocon Limited.

Company profile

• Sector: Healthcare
• Industry: Biotechnology
• Country: US
• Exchange: NASDAQ
• Employees: 55
• Website: https://www.bicara.com

Latest SEC filings for BCAX

• SCHEDULE 13G/A — 2026-10-07
• 8-K — 2026-08-25
• SCHEDULE 13G/A — 2026-08-13
• S-8 — 2026-08-11
• 8-K — 2026-08-11
• 10-Q — 2026-08-11
• 8-K — 2026-07-28
• 8-K — 2026-06-10
• 8-K — 2026-05-21
• SCHEDULE 13G — 2026-05-15

Latest BCAX news

• 2026-10-05 — Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Abrir análisis completo

Educational tool only — not investment advice.